Anti-CD7 monoclonal antibody-PAP conjugate

Drug Profile

Anti-CD7 monoclonal antibody-PAP conjugate

Alternative Names: Anti-CD7 pokeweed antiviral protein; Anti-CD7 pokeweed antiviral protein immunoconjugate; Anti-CD7 pokeweed antiviral protein immunotoxin; TXU pokeweed antiviral protein; TXU-PAP

Latest Information Update: 06 Nov 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wayne Hughes Institute
  • Class Antineoplastics; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Acute myeloid leukaemia; HIV infections; Leukaemia; Lymphoma

Most Recent Events

  • 06 Nov 2002 No development reported - Phase-I for Acute myeloid leukaemia in USA (unspecified route)
  • 06 Nov 2002 No development reported - Phase-I for HIV infections treatment in USA (IV-infusion)
  • 06 Nov 2002 No development reported - Phase-I for Leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top